BEAM Earnings & Financial Statements
Beam Therapeutics Inc.
$24.07
+$0.42(+1.75%)
43
Overall
60
Value
20
Tech
50
Quality
Market Cap
$2.44B
Volume
714.39K
52W Range
$20.23 - $38.26
Target Price
$48.11
BEAM earnings and financial statements: Beam Therapeutics Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
BEAM Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $139.74M | $63.52M | $377.71M | $60.92M | $51.84M |
| Operating income | -$383.69M | -$415.57M | -$176.49M | -$338.48M | -$392.46M |
| EBITDA | -$57.70M | -$354.78M | -$101.63M | -$271.53M | -$385.01M |
| Net income | -$79.99M | -$376.74M | -$132.53M | -$289.09M | -$370.64M |
| EPS (diluted) | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.48B | $1.10B | $1.46B | $1.34B | $1.47B |
| Total liabilities | $242.82M | $370.28M | $478.38M | $608.24M | $647.72M |
| Shareholders’ equity | $1.24B | $733.54M | $981.33M | $733.47M | $826.74M |
| Cash and equivalents | $294.94M | $281.97M | $435.89M | $232.77M | $559.99M |
| Long-term debt | $139.76M | $147.96M | $159.91M | $168.63M | $137.82M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$345.10M | -$347.25M | -$149.19M | $22.53M | -$66.27M |
| Capital expenditure | -$14.95M | -$8.95M | -$33.73M | -$48.95M | -$46.81M |
| Free cash flow | -$360.05M | -$356.19M | -$182.93M | -$26.42M | -$113.08M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BEAM | $24.07 | +1.8% | 714.39K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |